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Curcumin, the major curcuminoid of the turmeric, has been extensively used in many
countries since ancient time for preventing and/or treating a multitude of diseases. This
review is to illustrate the researches on the properties of curcumin and its potential
therapeutic efficacy in major anterior segment eye diseases. The bio-medical potential
of curcumin is restricted because of its low solubility and digestive bioavailability. This
review will discuss promising research in improving curcumin bioavailability through
structural modification. In vitro and in vivo research made progress in studying the
beneficial effects of curcumin on major anterior segment eye diseases, including anti-
angiogenesis effect in corneal diseases; anti-inflammation or anti-allergy effects in
dry eye disease, conjunctivitis, anterior uveitis; anti-proliferation and pro-apoptosis
effects in pterygium; anti-oxidative stress, anti-osmotic stress, anti-lipid peroxidation,
pro-apoptosis, regulating calcium homeostasis, sequestrating free radicals, protein
modification and degradation effects in cataracts; neuroprotective effects in glaucoma.
Curcumin exhibited to be a potent therapeutic candidate for treating those anterior
segment eye diseases.
Keywords: curcumin, corneal diseases, dry eye, conjunctivitis, anterior uveitis, pterygium, cataract, glaucoma
INTRODUCTION
Curcumin is a yellow-colored polyphenol that is isolated from the plant Curcuma-Longa and is
the principal curcuminoid of the popular spice turmeric. It has been used in various curcumin-
based products including energy drinks, ointments, capsules, tablets, soaps, cosmetics, and
traditional medicines for centuries. Curcumin is extensively used as a supplement in China,
India, USA, South Africa, Pakistan, Japan, Thailand, Korea, Siddha, and Chinese medicine
for the management of various diseases and conditions, such as wounds, inflammation, and
cancers (Strimpakos and Sharma, 2008; Aggarwal and Sung, 2009; Prasad et al., 2014). Curcumin
has been considered as an effective drug for various respiratory conditions in traditional
Chinese medicine, including allergy, asthma, bronchial hyperactivity and other disorders
(sinusitis, coryza, cough, anorexia, and hepatic diseases) (Rahman et al., 2006). During the
Abbreviations: AR, Aldose reductase; CNLC, cationic nanostructured lipid carriers; GSH, Glutathione; GST, Glutathione
S-transferase; IL-1β, interleukin-1 beta; I/R, ischemia/reperfusion; LPO, Lipoperoxides; MMP, matrix metalloprotein;
NF-κB, nuclear factor kappa-light-chain-enhancer of activated B cells; NPs, nanoparticles; NSAIDs, Non-Steroidal Anti-
inflammatory Drugs; NV, neovascularization; STZ, streptozotocin; TNF-α, tumor necrosis factor-α; VEGF, vascular
endothelial growth factor.
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last three decades, various studies concluded that curcumin has
anti-oxidant, anti-inflammatory, anti-angiogenic, and wound-
healing effects (Maheshwari et al., 2006; Zhang et al., 2015).
The pathologic mechanisms of major blinding anterior
segment eye diseases, such as corneal NV, glaucoma, and
cataracts, are often related to inflammation, oxidative stress-
mediated response, and angiogenesis. There is substantial
evidence that suggest the potential health benefits of curcumin
in diets and drugs to prevent the vision threatening eye diseases
(Huynh et al., 2013). This review summarizes the mechanisms
underlying the effects of curcumin on anterior segment eye
diseases.
METHODOLOGY
The PubMed database was searched with the terms “curcumin,”
“curcuminoid”, “curcuminoids”, “Curcuma longa,” “turmeric”,
“haridra”, “diferuloylmethane”, and “eye”, “ocular”, either alone
and in combination. Articles related with anterior segment eye
diseases were picked out manually. All articles with English
abstract were included, including those published in other
language.
BIOLOGICAL ACTIVITIES OF CURCUMIN
Curcumin was discovered in 1815, and subsequently identified
as 1,7-bis- (4-hydroxy-3-methoxyphenyl)-1,6- heptadiene-3, 5-
dione that exhibits keto-enoltautomerism, having an enol form
in alkaline media and a keto form in neutral and acidic solutions
(Anand et al., 2008). It is supposed to play an important role
in many animal disease models. This polyphenol has been
considered as an efficacious and safe agent in clinical trials, and
curcumin has been approved as a “generally regarded as safe”
compound by the U.S. Food and Drug Administration.
Anterior segment eye diseases include conjunctivitis
associated with inflammation, cataracts associated with
hyperglycemia and oxidative stress, pterygiums associated
with excessive proliferation, and other diseases. Varieties
of functions of curcumin have also been explored recently,
including its anti-inflammatory effects, anti-oxidant activity,
hypoglycemic effects, and anti-tumor (breast, prostate, lung,
pancreas, ovary, bladder, cervix, head and neck, brain, kidney,
and skin) effects (Chen et al., 2006; Strimpakos and Sharma,
2008; Prasad et al., 2014; Bimonte et al., 2015; Zhang et al.,
2015) Curcumin can also induce cell death in human uveal
melanoma cells through mitochondrial pathway (Lu et al., 2010).
All of aforementioned bio-functions contribute to the potential
beneficial effects of curcumin on anterior segment eye diseases.
SYNTHETIC ANALOGS OF CURCUMIN
IN OCULAR
It is still considered a challenge for topical therapy to corneal
diseases because tear fluids can wash the eye drops away
rapidly (Joseph et al., 2016). At same time, the anatomical
structure of the cornea causes a natural barrier for drug to
penetrate through the cornea into anterior chamber (Chang
et al., 2001). Though its safety and efficacy well-established,
so far curcumin has not been applied as a therapeutic drug,
perhaps, due to its relatively low aqueous solubility (Anand et al.,
2007). However, a lot of reports mention that bioavailability
might not be a problem. Different types of formulations that
have been made with curcumin are to enhance bioavailability
through various strategies. The thermo-sensitive gelling
agent and nanogel combining CNLC has been designed
to enhance the potentials for ocular permeation capacity
of curcumin. The developed Curcumin-CNLC-GEL could
significantly augment the bioavailability of curcumin and
sustain drug concentration in aqueous humor after dispensation
in comparison with that of the control group. Those results
indicated that Curcumin-CNLC-GEL could become a potential
formulation for the enhancement of solubility of curcumin
in the aqueous humor by enhancing corneal diffusion and
retaining capacity (Liu et al., 2016). Another study reported
that methoxypoly (ethylene glycol)-poly (ε-caprolactone)
diblock copolymers (MePEG-PCL) nanoparticle of curcumin
enhances retention of curcumin in the cornea, and improves
corneal NV over curcumin (Pradhan et al., 2015). Jie et al.
tested an ophthalmic in situ gel made of curcumin-loaded
nanoparticles (Cur-BSA-NPs-Gel), and found that curcumin-
loaded albumin nanoparticles (Cur-BSA-NPs-Gel) scored
superior sustained-release result, and concluded albumin
nanoparticles (Cur-BSA-NPs-Gel) exhibit little effects on the
gel structure in vitro. The in vivo study also indicated that
the formulation might greatly increase bioavailability of the
curcumin in the aqueous humor. Therefore, the curcumin-
loaded albumin nanoparticles (Cur-BSA-NPs-Gel) system
depicted that an ophthalmic delivery system that may prolong
drug retention time and enhanced ocular bioavailability (Lou
et al., 2014). Ion-sensitive curcumin-loaded Pluronic P123
(P123)/D-a-tocopheryl polyethylene glycolsuccinate (TPGS)
mixture of micelle in situ gels (CUR-MM-ISGs) prepared by
Yu et al. prolonged ocular residence time and greatly enhanced
cornea permeability, and these findings showed that the
biocompatible CUR-MM-ISGs had significant potentials for
effective ophthalmic drug therapy (Duan et al., 2015). A novel
demethylated curcuminoid compositon exhibited superior
anti-inflammatory and neuroprotective efficacy compared to
curcuma longa extract. Demethylated curcuminoid composition
was classified as mildly irritating to the eye based on the
primary eye irritation test on rabbits (Krishnaraju et al., 2009).
An adjunctive-to-traditional medicine with Norflo tablets
(curcumin-phosphatidylcholine complex) was given two times
a day in various recurrent anterior uveitis. It is illustrated
that Norflo tablets was well endured and could potentially
minimize ocular discomfort several weeks later in almost 80% of
patients (Allegri et al., 2010). Other curcumin based formulation
was also reported that are made to owing more biological
activities than curcumin (Shoji et al., 2008; Liu et al., 2011;
Das and Sahoo, 2012; Steigerwalt et al., 2012; Grama et al.,
2013).
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CURCUMIN AS A PROMISING
THERAPEUTIC CANDIDATE FOR
ANTERIOR SEGMENT EYE DISEASES
Cornea Diseases
Inhibiting Corneal NV
The cornea is the transparent avascular anterior part of the
eye. Corneal NV is a condition in which excessive blood vessels
grow into the cornea and is the leading cause of blindness. This
condition is trigged by corneal hypoxia, inflammation, and/or
limbal barrier dysfunction. Currently, the treatments for corneal
NV include steroids, nonsteroidal anti-inflammatory eye drops,
fine needle diathermy, photodynamic therapy, and anti-VEGF
therapy (Chang et al., 2001). Though, these therapies ameliorate
corneal NV to some extent, the side effects cannot be ignored:
steroids may cause corneal thinning, ocular hypertension,
and cataracts (Sarchahi et al., 2008); NSAIDs may lead to
corneal ulceration and perforation (Guidera et al., 2001); fine
needle diathermy and photodynamic therapy may cause an
inflammatory response (Shakiba et al., 2009; Koenig et al., 2012);
and anti-VEGF therapy complications include corneal thinning,
reduced epithelial healing (Kim et al., 2008), and epithelial
erosion (Oh et al., 2009). Therefore, a safe and effective therapy
for corneal NV is needed.
Vascular endothelial growth factor and basic fibroblast growth
factor (bFGF) are supposed to attract and recruit inflammatory
cells, leading to corneal NV. Curcumin could inhibit proliferation
of primary endothelial cells cultured in vitro, either in the
presence or absence of bFGF (Arbiser et al., 1998). It was able
to prohibit bFGF-induced mouse corneal NV in vivo (Arbiser
et al., 1998). Suturing-induced rabbit corneal NV could also be
suppressed by curcumin, in vivo (Kim et al., 2010) via decreasing
the VEGF mRNA levels and phosphorylation of NF-κB (Kim
et al., 2010). Curcumin NPs might significantly reduce angiogenic
sprouting in a dose and time dependent manner in the mouse
aortic ring in vitro. Curcumin NPs were also able to inhibit
NF-κB in LPS-induced corneal cells in vitro (Pradhan et al., 2015).
It may also prohibit corneal angiogenesis in silver nitrate-induced
corneal NV in vivo through the mechanism of inhibiting VEGF,
inflammatory cytokines [IL-1β, TNF-α], and MMPs (MMP-2
and MMP-9) (Pradhan et al., 2015). Curcuminoids, administered
locally or in the diet, could suppress fibroblast growth factor-2
(FGF-2)-induced rabbit corneal NV in vivo, by inhibiting DNA
binding activity from transcription factor activator protein-1
(AP-1) and gelatinase B promoter activity (Mohan et al., 2000).
The effects and mechanisms of curcumin and curcumin NPs on
corneal diseases warrant an effective and safe herbal therapy for
preventing corneal NV (Figure 1).
Protecting Corneal Epithelial Barrier
The corneal epithelium provides a strict barrier that is both
useful for dependent on tight junctions between adjacent
epithelial cells and corneal homeostasis. Barrier function of the
corneal epithelium can be undermined by bacterial infection or
inflammation, resulting in different conditions of the epithelium
and in stromal edema, infection, or melting. Kimura et al. (2008)
found that TNF-α or IL-1β could damage the human corneal
epithelial cells barrier in vitro by affecting the localization of the
tight junctions proteins zonula occludens-1 at tight junctions
dependent on NF-κB. Curcumin could inhibit both TNF-α and
IL-1β induced subcellular localization of occludens-1 through
NF-κB inhibition in vitro, indicating curcumin may prevent
corneal epithelial barrier function disruption related with ocular
inflammation (Kimura, 2010).
Promoting Corneal Wound Healing
Diabetes increases the risk of corneal diseases, and as high as 50%
of diabetic patients suffered from diabetic keratopathy (Zagon
et al., 2007), including reduced corneal sensitivity, decreased
tear secretion, tear film dysfunction, degeneration of nerve
fibers, loss of corneal epithelia, and corneal ulcer (Gao et al.,
2015). The current treatments for diabetic keratopathy include
artificial tears, antibiotic eye drops, tarsorrhaphy, and bandage
contact lens, which helps for corneal wound healing (Abdelkader
et al., 2011). However, these measures may not be effective and
adequate at accelerating re-epithelialization in diabetes, even if
different therapies are used simultaneously. Thus, novel effective
methods are required.
Guo et al. reported intranasal nanomicelle curcumin promotes
corneal epithelial/nerve wound healing in STZ-induced diabetic
mice with corneal epithelium abrasion. The mechanism includes
alleviating free radical scavengers, recovering the enhanced
accumulation of reactive oxygen species (ROS), decreased mRNA
expressions of neurotrophic factors, and increased mRNA
expressions of inflammatory cytokines in the cornea. Trigeminal
ganglion neurons were also observed in mice with corneal
epithelium abrasions. These findings illustrate that intranasal
curcumin could effectively promote diabetic corneal epithelial
or nerve wound healing. This treatment might be a promising
therapy for diabetic keratopathy (Guo et al., 2016).
Dry Eye Disease
Dry eye disease is one of the most prevalent eye diseases, with
an estimated ten million individuals affected in the United
States (Niederkorn et al., 2006). Decreased secretion of the tears
and rapid tear evaporation are the two contributing factors for
dry eye disease. Increased tear osmolality and ocular surface
inflammation are involved in the pathogenesis of ocular surface
damage during the course of the disease. Different types of anti-
inflammatory drugs like topical corticosteroid usually improve
the symptoms of the disease in short term trials (Yang et al.,
2006). Unfortunately, in the long run, some serious potential
side effects limit its use (Lemp, 2007). So far, all the available
drugs have some limitations, which call for the need to develop
more potent drugs for the treatment of dry eye disease. The
possible mechanisms of curcumin on dry eye disease are still
unclear. Increased tear osmolality is an important feature of
the disease. In a hyperosmotic environment, pro-inflammatory
cytokines such as interleukin-6 (IL-6), interleukin-8 (IL-8), and
IL-1β are detected in corneal cell lines or dry eye patients
(Solomon et al., 2001; Li et al., 2006; Chotikavanich et al., 2009).
Curcumin could inhibit ovalbumin-induced pro inflammatory
cytokines [interleukin-4 (IL-4), interleukin-5 (IL-5)] expression
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FIGURE 1 | The effects and mechanisms of curcumin and curcumin NPs on corneal diseases. Cur, Curcumin; NPs, curcumin nanoparticles. Thin arrows
show direct reactions, and dotted arrows indicate indirect reactions.
in conjunctiva in mice (Chung et al., 2012). Our previous study
showed that curcumin guarded against hyperosmoticity-induced
IL-1β upregulation in corneal epithelial cell in vitro through
p38 mitogen-activated protein kinase (MAPK)/NF-κB pathways
(Chen et al., 2010), which indicates that curcumin might serve as
a promising candidate for treating dry eye disease.
Conjunctivitis
Conjunctivitis is one of the most frequently occurring ocular
diseases worldwide. It can be caused by bacteria, viruses, and
allergies. Conjunctivitis is becoming increasingly prevalent due
to the resilient bacterial strain infections, changing climate,
increased pollen loads, pollution, and the resulting heightened
immunological response to the environmental changes. There
are many ocular medications for treating conjunctivitis but
they are expensive and the long treatment period increases the
risk of microbial resistance. An inexpensive and low side-effect
treatment is needed, especially in developing countries.
Ophthacare, obtained from the Himalaya Drug Company, is
the brand name of a mixed herbal eye drop with 8 different
herbs, – including curcuma-longa (rhizome) 1.30% w/v –
was reported to have positive effects to treat conjunctivitis,
conjunctival xerosis (dry eye), etc. (Biswas et al., 2001). In
a previous study, it was reported to have effects in different
ophthalmic diseases namely, conjunctivitis, conjunctival xerosis
(dry eye), etc. (Biswas et al., 2001). The study showed that
OphthaCare can be safely administered in various infective and
inflammatory conjunctival diseases, but has still yet to be assessed
in a double-blind clinical trial. Haridra (Curcuma-Longa) is
available freely in India and in tropics, and Haridra Eye Drops
was reported to have an important role in treating bacterial
conjunctivitis in a clinical study. Bacteriological study shows
the Haridra has an active role against Escherichia coli (E. coli),
St. Aureus, Klebshella, and pseudomonas organisms (Srinivas
and Prabhakaran, 1989). Curcumin was reported to suppress
ovalbumin-induced allergic conjunctivitis in an experimental
mice model (Chung et al., 2012). Mice challenged with ovalbumin
via the conjunctival sac following systemic sensitization in
aluminum hydroxide had severe allergic conjunctivitis. Pre-
administration of curcumin 1h before ovalbumin challenge
could markedly inhibit the activation of inducible nitric oxide
synthase (iNOS) production in the mice conjunctiva and
suppress immunoglobulin E (IgE)-mediated and eosinophil-
dependent conjunctival inflammation. Inhibition of IL-4 and IL-
5 expression in conjunctiva, cervical lymph nodes, and spleen was
observed in mice treated with curcumin, when compared to mice
challenged with ovalbumin. These results indicate that curcumin
suppresses allergic conjunctivitis through its anti-allergic and
anti-inflammation properties.
Pterygium
Pterygium is an inflammatory and degenerative ocular surface
disease in which the conjunctiva on the cornea grows to
form fibrous tissue in a triangular shape. The pathogenesis
is not completely understood, but recent evidence suggests
that pterygium is histologically composed of proliferating fibro
vascular tissue and is correlated strongly with exposure to
ultraviolet radiation (Yam and Kwok, 2014; Shah et al., 2016).
Surgical excision is the first-choice treatment for pterygium, but
the high recurrence rate is a burden for patients. Therefore,
the treatment of pterygium remains quite controversial. The
identification of effective drugs for the treatment of pterygium
is urgently needed. Curcumin (20–80 µmol/L) was found
to hinder the expression of spreading cell nuclear antigen
and to stop the proliferation and cause the cell death of
human pterygium fibroblasts both in a dose-and time-dependent
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manner, indicating that curcumin had a potential therapeutic
outcome against pterygium (Zhang et al., 2007). However, the
study was restricted to in vitro experiment. Biswas et al. (2001)
documented that OphthaCare showed an excellent response in
the treatment of pterygium.
Anterior Uveitis
Anterior uveitis is associated with inflammation of the uveal
tract (especially the iris) and without intervention can cause
blurry vision and permanent damage to the eye. It is the
fourth most common cause of blindness in developed countries
(Chang and Wakefield, 2002; Merida et al., 2015). The underlying
mechanism of uveitis is unclear due to its heterogeneity.
Corticosteroid and NSAIDs are the main available treatment for
uveitis. However, side-effects (i.e., cataract, secondary glaucoma,
anterior, and posterior synechiae) are commonly observed with
steroid therapy. Corticosteroid can only provide some short-
term relief, but not significant long-term relief. An alternative
therapeutic that could relieve inflammation like a corticosteroid,
but without any adverse side effects is needed.
It was reported that curcumin could treat chronic anterior
uveitis without any adverse side effects (Lal et al., 1999).
Curcumin was filled in capsules (375 mg curcumin/capsule)
and taken orally by patients with chronic anterior uveitis.
Patients took one capsule t.i.d. along with local cyclopegics (e.g.,
atropine/cyclopentolate1%) improved their vision significantly
with decreased aqueous flareand keratic precipitates (Lal et al.,
1999).
Meriva (Indena, Milano, Italy) is a product-curcumin
formulated with phosphatidylcholine-which improves
bioavailability at least 10 times compared to standard curcumin
(Marczylo et al., 2007). It exhibited a beneficial effect in the
adjunctive therapy of recurrent anterior uveitis with different
etiologies, including herpetic (cytomegalovirus, Epstein–Barr
virus, varicella zoster virus, and herpes simplex virus) uveitis,
autoimmune (overlap syndrome, sarcoidosis, rheumatoid
arthritis, and systemic lupus erythematosus) inflammatory
ocular disease, and different origin anterior uveitis (seven
toxoplasmic etiology, eight unknown origin, four Lyme disease,
and three tuberculosis), with the most sensitive being for
autoimmune uveitis, and more relapsing against herpetic uveitis
(Allegri et al., 2010). Various mechanisms for these beneficial
effects of curcumin have been proposed. Topically applied
standardized aqueous extract of Curcuma-Longa suppresses
E. coli lipopolysaccharide-induced anterior uveitis in rats
(Agarwal et al., 2013) and rabbits (Gupta et al., 2008) by reducing
TNF-α activity (Agarwal et al., 2013). Curcumin may also
stabilize the lysosomal membranes (Srivastava and Srimal,
1985; Dikshit et al., 1995), inhibit leukotrienes (Flynn et al.,
1986; Ammon et al., 1992) and thromboxane B4 (Srivastava
and Srimal, 1985). It possesses strong free radical scavenging
(Zhao et al., 1989) and anti-oxidant properties (Rajakumar and
Rao, 1994). It was found to prompt nitric oxide synthesis in
activated macrophages and to inhibit neutrophil activity (Brouet
and Ohshima, 1995). Its beneficial effect may be related to
the anti-fibrinolytic activity for breaking the anterior and the
posterior synechiae (Lal et al., 1999).
Compared with corticosteroids, curcumin exhibits an
advantage in lacking adverse side effects in the treatment of
chronic anterior uveitis.
Cataract
Cataracts accounts for more than one third of blindness globally
(Resnikoff et al., 2008). Twenty-five percent of people over the
age of 65 and 50% of people over the age of 80 have a serious loss
of vision due to cataracts (Foster and Resnikoff, 2005). Cataract
extraction surgery is the mainstream treatment for cataract.
While cataract surgery is considered to be safe and mature,
irreversible blindness is a potential risk. There is no recognized
medication which can cure or reverse cataract. If cataract onset
is delayed by 10 years, it is estimated to reduce the possibility for
cataract surgery by 50% (Kupfer, 1985). Thus, much emphasis is
being laid on identifying compounds with high effectiveness and
low toxicity that can either prevent the onset or delay cataract
progression.
Anti-oxidative Stress
It is believed that oxidative damage to the eye lens contributes to
the development of different kinds of cataracts (Suryanarayana
et al., 2005; Manikandan et al., 2010a,b). The primary mechanism
for the anti-cataract effect of curcumin is through its antioxidant
properties (Manikandan et al., 2009, 2010a, 2011; Radha et al.,
2012).
Curcumin may inhibit peroxiredoxin 6 (a pleiotropic
oxidative stress-response protein) in cultured human lens
epithelial cells (hLECs) in vitro (Chhunchha et al., 2011).
Bioactive derivatives of curcumin (salicylidenecurcumin CD1
and benzalidenecurcumin CD2) were reported to inhibit the
selenite induced cataract by reversing the activity of antioxidant
enzymes, decreasing ROS, and increasing the activities of
superoxide dismutase (SOD) (Manikandan et al., 2010a; Radha
et al., 2012).
Curcumin was found to have a protective effect against
cataract development and/or progression in numerous in vitro
and in vivo cataract models (Awasthi et al., 1996; Pandya
et al., 2000; Suryanarayana et al., 2003, 2005; Kumar et al.,
2005a,b; Raju et al., 2006; Manikandan et al., 2009, 2010a,b, 2011;
Grama et al., 2013). It may suppress selenium-induced oxidative
stress in rat organ cultured lens and delay the formation of
cataracts by inhibiting the non-enzymic antioxidants depletion
(Manikandan et al., 2009). Vitamin C is a potent non-enzymic
antioxidant, and the level of Vitamin C is high in human
lens, suggesting that vitamin C may have a preventive role in
cataract progression. The decreased vitamin C levels observed
in selenite-induced rat cataracts suggests that weakened non-
enzymatic antioxidant defenses may play a role in selenite-
induced rat cataracts. Administration of curcumin was found to
increase vitamin C levels (Murugan and Pari, 2006). Pretreatment
of curcumin may prevent oxidative damage and delay the
development of cataracts by increasing superoxidase dismutase
and catalase enzyme activity in Wistar rats (Padmaja and Raju,
2004). Curcumin may prevent alterations of protein carbonyls,
antioxidant enzymes glutathione peroxidase (GPx), glucose-6-
phosphate dehydrogenase (G6PD) and significantly decreased
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GSH levels, demonstrating curcumin delay the progression
of diabetic cataract by preventing hyperglycemia-mediated
lenticular oxidative stress in rats (Suryanarayana et al., 2005).
Anti-lipid Peroxidation Stress
Lipoperoxides is enhanced in selenite-induced rat cataract
in vivo (Manikandan et al., 2010b). Hiobarbituric acid-reacting
substances (TBARS), commonly measured as a marker of LPO,
was also elevated in rat of selenite-induced and STZ-induced
cataract in vivo (Suryanarayana et al., 2005; Manikandan et al.,
2010b), indicating enhanced lipid peroxidation in cataracts.
Curcumin significantly delayed the progression and maturation
of cataracts in a dose-dependent manner by decreasing LPO
and TBARS (Suryanarayana et al., 2005; Manikandan et al.,
2010b). GST is a group of multifunctional proteins that performs
tasks ranging from catalyzing the detoxification of electrophilic
compounds to protecting against peroxidative damage (Sener
et al., 1979). GST is decreased in selenite-induced rat cataracts
in vivo, and curcumin increased the activity of GST to
near normal level (Manikandan et al., 2010b). 4-hydroxy-2-
transnonenal (4-HNE) is a highly electrophilic product of lipid
peroxidation. It was reported that curcumin has a protective
effect on organ-cultured lens in 4-HNE induced cataract
formation. Curcumin treatment caused an induction of the GST
isozymer GST8-8 in rat lenticular epithelium. GST8-8 uses 4-
HNE as a favorable substrate, suggesting the beneficial effect
of curcumin may be regulated by producing this GST isozyme
(Suryanarayana et al., 2005; Manikandan et al., 2010b). GSH is
believed to prevent the cells from lipid peroxidation. GSH is
known as a free radical scavenger, a cofactor for many enzymes
and a co-substrate for glutathione peroxidase (GPx) activity
(Gregus et al., 1996). Selenite increases lipid peroxidation in rat
lens, leading to downregulation of GSH in the lens. Curcumin
pretreatment resulted in maintaining normal GSH levels that was
detected in tissues and serums in selenite treated lenses in vivo,
indicating the protective role of curcumin against oxidative stress
(Manikandan et al., 2010b).
Vitamin E, a natural lipid soluble antioxidant, can maintain
the integrity of cell membrane and vital membrane functions
by inhibiting lipid peroxidation. Vitamin E was reported to
have a protective effect in delaying galactose-induced cataract
formation and aminothiazole-induced cataract formation in
rabbits, inhibiting the lipid photo-peroxidation in lens, limiting
radiation related lenticular damage, and preventing diabetic
cataract or heat-induced cataract formation (Creighton et al.,
1985; Gregus et al., 1996). The level of vitamin E in lens
homogenate was decreased in rat treated with selenite alone, and
early administration of curcumin produced a protective effect on
vitamin E levels (Manikandan et al., 2010b). Curcumin in a 0.01%
dose, supplemented with vitamin-E, inhibited galactose-induced
rat cataract in vivo by inhibiting lipid peroxidation (Raju et al.,
2006).
Anti-osmotic Stress
Aldose reductase, a vital enzyme for polyol pathway, was
significantly increased in STZ-induced diabetic rat lens.
Curcumin normalized AR activity in vivo, indicating curcumin
is effective against osmotic stress caused by hyperglycemia
(Suryanarayana et al., 2005; Grama et al., 2013).
Protein Modification and Degradation
Studies have shown that even in the earliest stages of cataract
formation, the pattern of lens proteins changed (Manikandan
et al., 2010a). Significant decreases were found in β crystallins,
gamma (γ)-crystallins, and a high molecular weight (HMW)
aggregate peak in STZ-induced diabetic rat lens by High
Performance Liquid Chromatography (HPLC). The proportion
of cross-linked and aggregated proteins were detected to be
increased in the soluble protein in STZ-induced diabetic rat
lens, suggesting either aggregation or cross-linking might or
any unknown factor might be causing protein modification and
degradation in diabetic cataractous lens, leading to the formation
of HMW aggregates. The insolubility of otherwise soluble protein
and alterations in protein profile can result in lens opacification
(Kumar et al., 2005b; Suryanarayana et al., 2005). Curcumin and
turmeric remarkable alleviated those protein changes, indicating
that curcumin and turmeric has a protective effect against
diabetic cataract in rats (Kumar et al., 2005b; Suryanarayana
et al., 2005). Heat shock protein 70 (Hsp 70), αA-crystalline,
αB-crystallin were the predominant constituent proteins which
maintain eye lens transparency, and were increased in cataracts.
Curcumin could suppress the expression of Hsp 70, αA-
crystalline, and αB-crystallin in STZ or selenite-induced cataracts
in rat. (Kumar et al., 2005a; Manikandan et al., 2011).
Calcium Homeostasis
Although the precise mechanisms of cataracts are not fully
elucidated, a plausible mechanism might be that constant
oxidative stress causes progressive deterioration of Ca2++
homeostasis (Hightower and McCready, 1989). Ca2+ is essential
for maintenance of lens transparency, and increased Ca2+ could
activate calpain which can degrade crystallins in lens, leading
to cataract formation (Shearer and David, 1982; Thiagarajan
and Manikandan, 2013). It was reported that Ca2+ ATPase may
participate in regulating Ca2+ homeostasis in lens (Manikandan
et al., 2010a). Curcumin may decrease selenite-induced increase
of Ca2+ concentration in selenium-induced rat cataract model
in vivo by increasing the activities of Ca2+ ATPase and thus
lowering the Ca2+ to an almost normal level (Manikandan et al.,
2010a).
Anti-nitrosative Stress and Scavenge Free Radicals
Excessive free radical generation (NO, OH−, O2−) has been
identified as one of the major etiological factors of cataracts
(Spector, 1995). An excess of NO, produced by inducible nitric
oxide synthases (iNOS), is thought to cause cell injury by
nitrosative stress and contribute to cataract formation (Ito et al.,
2001; Ornek et al., 2003; Manikandan et al., 2010a). OH−
is also a highly reactive free radical that contributes to lens
crystalline modification (Fu et al., 1998). OH− could react
with NO, generating more reactive compounds (Graham et al.,
1993). Curcumin has been reported to be able to sequestrate
free radicals, and scavenge NO, OH−, O2− in isolated rat
peritoneal macrophage in vitro (Joe and Lokesh, 1994). Curcumin
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TABLE 1 | Selected observational studies on the relationship between curcumin and cataract models.
Type Models Oberservation Results Reference
In vitro Cultured human LEC Effect of curcumin on
peroxiredoxin 6 in
ROS-induced oxidative
stress-response in human LEC
Curcumin protects LEC by upregulating peroxiredoxin 6 transcription via
invoking specificity protein 1 (Sp1) activity against proapoptotic stimuli.
Chhunchha
et al., 2011
Cultured bovine LEC Effect of curcumin on apoptosis
of LEC
Curcumin induced apoptosis of LEC by decreasing of DNA content in
LEC nucleus and collapsing of DeltaPsim in cytoplasm.
Huang et al.,
2006
Rat organ cultured lens Effect of curcumin and its
derivatives (CD1, CD2) on
selenite-induced cataract
Curcumin and its derivatives (CD1, CD2) are beneficial against
selenite-induced cataract by reversing the activity of antioxidant
enzymes and calcium homeostasis to near normal levels in lens.
Radha et al.,
2012
Rat organ cultured lens Effect of curcumin on
4-HNE-induced opacification of
lens
Lens from diatary curcumin-treated rats were much more resistant to
4-HNE-induced opacification than control group.
Awasthi et al.,
1996
Rat organ cultured lens Effect of curcumin on
selenium-induced oxidative
stress in lens
Curcumin suppressed oxidative stress and cataract formation,
prevented uncontrolled generation of free radicals, and inhibited iNOS
expression.
Manikandan
et al., 2009
In vivo Selenium-induced rat
cataract
Effect of curcumin on Ca2+
ATPase in selenium-induced
cataract
Diatary curcumin prevented selenium-induced Ca2+ ATPase activation
and inhibited cataract.
Manikandan
et al., 2010a
Selenium-induced rat
cataract
Effect of curcumin on αA- and
αB-crystallin and heat shock
protein 70 in selenite-induced
cataract
Diatary curcumin decreased selenium-induced the αA- and
αB-crystallin and Hsp 70 production.
Manikandan
et al., 2011
Selenium-induced rat
cataract
Antioxidant effect of curcumin
on selenium-induced cataract
Dietary curcumin prevented oxidative damage and delay the
development of cataract by attenuating lipid peroxidation, xanthine
oxidase enzyme activity and increasing superoxidase dismutase and
catalase enzyme activity.
Padmaja and
Raju, 2004
Selenite-induced rat
cataract
Antioxidant effect of curcumin
on selenite-induced cataract
Diatary curcumin decreased LPO, enzymic antioxidants, and
nonenzymic antioxidants induced by selenite.
Manikandan
et al., 2010b
Naphthalene-induced
rat cataract
Effect of curcumin on
naphthalene-induced
opacification of lens
Dietary curcumin alleviated naphthalene-induced cataract by
attenuating apoptotis of LECs.
Pandya et al.,
2000
Galactose-induced rat
cataract
Effect of curcumin on
galactose-induced cataract
Diatary curcumin delayed the onset and maturation of cataract by
antioxidant and antiglycating effects, as it inhibited lipid peroxidation,
AGE-fluorescence, and protein aggregation.
Suryanarayana
et al., 2003
Galactose-induced rat
cataract
Effect of vitamin-E and
curcumin on galactose-induced
cataract
Combination of diatary vitamin-E and curcumin delayed the on the
onset and maturation of galactose-induced cataract with an antioxidant
effect, as it inhibited lipid peroxidation and contributed to a distinct rise
in reduced GSH content.
Raju et al.,
2006
STZ-induced rat
diabetic cataract
Effect of curcumin and its
source (turmeric) on
STZ-induced diabetic cataract
Dietary curcumin delayed the progression of cataract, with reversed
change in lipid peroxidation, reduced GSH, protein carbonyl content
and activities of antioxidant enzymes, preventing aggregation and
insolubilization of lens proteins due to hyperglycemia.
Suryanarayana
et al., 2005
STZ-induced rat
diabetic cataract
Effect of curcumin NPs on
STZ-induced diabetic cataract
Oral nanocurcumin was effective than curcumin in delaying diabetic
cataracts in rats, attributed to its ability to intervene protein
insolubilization, polyol pathway, protein glycation, crystallin distribution,
and oxidative stress.
Grama et al.,
2013
STZ-induced rat
diabetic lens
Effect of curcumin on αA- and
αB-crystallins in lens
Dietary curcumin attenuated the enhanced expression of αB-crystallin in
lens induced by STZ.
Kumar et al.,
2005a
STZ-induced rat
diabetic lens
Effect of curcumin on
α-crystallin chaperone activity in
lens
αH- and αL-crystallins isolated from curcumin fed diabetic rat lens had
shown improved chaperone-like activity as compared to control group.
Kumar et al.,
2005b
LEC, lens epithelial cells; STZ, Streptozotocin.
prevented uncontrolled generation of free radicals by inhibiting
the production of iNOS in selenium-stimulated organ cultured
lens of rat pups in vitro (Manikandan et al., 2009). Pretreatment
of curcumin was found to prevent free radical generation in
selenium-induced cataract in rat pups in vivo (Manikandan et al.,
2010a).
Inhibit Proliferation and Induce Apoptosis
Lens cell membrane damage is considered as one of the early
signs of cataractogenesis, resulting in changes in intraocular
metabolism and composition (Vrensen, 1995). Suppressing the
proliferation and inducing apoptosis of lens epithelial cells
is the primary goal in preventing cataractogenesis. Curcumin
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TABLE 2 | Selected observational studies on the relationship between curcumin and anterior segment eye diseases.
Region Models Oberservation Results Reference
Cornea Cultured HCE Effect of curcumin on TNF-α
induced corneal barrier
disruption
Curcumin blocked the TNF-α induced occludens-1
disappearance by suppressing the NF-κB pathway, and
it also blocked TNF-α decreased TER.
Kimura et al., 2008
Cultured HCE Effect of curcumin on IL-1β
induced corneal barrier
disruption
Curcumin blocked the effects of IL-1β on occludens-1
and occludin by suppressing the NF-κB pathway, and it
also blocked IL-1β decreased TER.
Kimura et al., 2009
Cultured HCE Effect of curcumin on dry eye
disease
Curcumin inhibited hyperosmoticity-induced IL-1β
elevation in HCE through P38 MAPK/NF-κB pathways.
Chen et al., 2010
Mouse model of corneal NV,
cultured bovine capillary
endothelial cells, MS1
endothelial cells line
Effect of curcumin on the
proliferation of endothelial cells
with bFGF, and bFGF-induced
corneal NV.
Curcumin inhibited bFGF-induced corneal NV in the
mouse cornea and both endothelial cells’ proliferation.
Arbiser et al., 1998
Rabbit and mouse model of
corneal NV
Effects of curcuminoids on
FGF-2-induced corneal NV
Localized and systemic delivery of curcuminoids
inhibited the angioproliferative response to FGF-2
stimulation in rabbit and mouse corneas.
Mohan et al., 2000
Rabbit model of corneal NV Effect of curcumin on
suturing-induced corneal NV
Topically curcumin inhibited suturing-induced corneal
NV and VEGF mRNA upregulation.
Kim et al., 2010
Aortic ring assay, rat model of
corneal NV
Effect of curcumin NPs on silver
nitrate-induced corneal NV
Topically curcumin NPs suppressed the expression of
VEGF, inflammatory cytokines, and MMP. It prevented
corneal NV by suppressing the NF-κB pathway.
Pradhan et al., 2015
STZ-induced diabetic mice
model with corneal epithelium
abrasion
Effect of nanomicelle curcumin
on corneal epithelial wound
healing
Intranasal nanomicelle curcumin effectively promoted
corneal epithelial/nerve wound healing in diabetic mice.
Guo et al., 2016
Conjunctiva Patients Effect of Curcuma-Longa on
bacterial conjunctivitis
Curcuma-Longa had an active role on E. Coli,
St. Aureus, Klebshella and pseudomonas organisms.
Srinivas and
Prabhakaran, 1989
Mice model of AC Effect of curcumin on
ovalbumin-induced AC
Curcumin inhibited the ovalbumin-induced iNOS
activation, IL-4 and IL-5 production in the mice
conjunctiva.
Chung et al., 2012
Conjunctiva/
Cornea
Cultured human pterygium
fibroblasts
Effect of curcumin on pterygium
fibroblasts
Curcumin stopped the proliferation and caused the cell
death of human pterygium fibroblasts.
Zhang et al., 2007
Uvea Patients Effect of curcumin on chronic
anterior uveitis
Orally curcumin improved patients’ chronic anterior
uveitis with improved vision, decreased aqueous flare,
and keratic precipitates.
Lal et al., 1999
Patients Effect of
curcumin-phosphatidylcholine
complex on recurrent anterior
uveitis
Orally curcumin-phosphatidylcholine complex improved
recurrent anterior uveitis in more than 80% of patients.
Allegri et al., 2010
E. coli
lipopolysaccharide-induced rat
uveitis
Effect of Curcuma-longa on
endotoxin-induced uveal
inflammation
Topical Curcuma-longa suppressed E. coli
lipopolysaccharide-induced uveitis in rats by reducing
TNF-α activity.
Agarwal et al., 2013
E. coli
lipopolysaccharide-induced rat
uveitis
Effect of topical
Curcuma-longa on
endotoxin-induced uveal
inflammation
Topical Curcuma-longa showed anti-inflammatory
activity against endotoxin-induced uveitis in rabbits.
Gupta et al., 2008
Lens see Table 1
Neuronal
/Glial
NMDA treated cultured retinal
neuronal/glial cells
Effect of curcumin on retinal
neuronal/glial cultures
Curcumin attenuates NMDA-induced apoptosis in
retinal neuronal/glial cultures by inhibiting the
phosphorylation of the NR1 subunit of the NMDA
receptor, showing curcumin possed neuroprotective
effects by inhibiting NMDA mediated excitotoxicity.
Matteucci et al., 2005
Cultured BV-2 microglia cell
line, rat model of chronic high
intraocular pressure
Neuroprotective effect of
curcumin on H2O2 treated
BV-2 microglia cell line and
microglia under chronic high
intraocular pressure
Curcumin increased the cell viability of H2O2-treated
BV-2 microglia and decreased the intracellular ROS and
apoptosis. It protected microglia from death in chronic
high intraocular pressure rat model. In both models,
caspase 3, cytochrome c, and BAX were
downregulated and BCL2 was upregulated in the
curcumin-treated group.
Yue et al., 2014
Staurosporine treated
transformed mouse RGC-5 and
mice
Effect of curcumin on death of
retinal ganglion cells
Curcumin attenuated RGC and amacrine cell loss, by
restoring NF-κB expression.
Burugula et al., 2011
(Continued)
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TABLE 2 | Continued
Region Models Oberservation Results Reference
Rat model of acute retinal I/R
injury
Effect of curcumin on retinal I/R
injury
Curcumin could reverse the decrease of mfn2 and the
increase of Nrf2 in the retinal I/R-induced glaucoma
model. It protected retinal neurons and microvessels
against I/R injury, may occur through its inhibitory
effects on injury-induced activation of NF-κB and
STAT3, and over-expression of MCP-1.
Wang et al., 2011
NV, neovascularization; HCE, human corneal epithelial cells; TER, transepithelial electrical resistance; RGC-5, retinal ganglion-like cells; Streptozotocin, STZ; AC, allergic
conjunctivitis.
FIGURE 2 | The mechanisms of the beneficial effects of curcumin on different anterior segment eye diseases.
could inhibit proliferation of human lens epithelial B3 (HLE-
B3) cells cultured in vitro (Hu et al., 2012). It may also induce
irreversible apoptosis in bovine lens epithelial cells cultured
in vitro, through attenuating mitochondrial transmembrane
potential in cytoplasm and decreasing DNA content in nucleus
(Huang et al., 2006). Further in vivo experiments are needed to
validate curcumin’s effects on proliferation and apoptosis in lens
epithelial cells.
Thus, as a viable food-based pharmacologic drug, numerous
studies (summarized in Table 1) have demonstrated that
curcumin may protect again cataracts and may serve as an
effective and low toxic medication for the prevention and
treatment of cataract.
Glaucoma
As a chronic, progressive, irreversible optic nerve neuropathy,
glaucoma has already affected more than 60 million people
worldwide by 2010 (Quigley and Broman, 2006), and the
number continues to grow. It is characterized by persistent
loss of retinal ganglion cells, thinning of the retinal nerve fiber
layer, and progressive loss of the vision field (Quigley, 1993).
However, the exact underlying pathological mechanisms remain
unclear. Elevated intraocular pressure is the most critical risk
for glaucoma, and it was reported to cause damage to the optic
nerve through retinal ganglion cell apoptosis (Ritch, 2007). The
most important clinical treatment is lowering the intraocular
pressure, using eye drops, oral medications or surgeries. But
lowering the intraocular pressure only slows down glaucoma
progress, rather than preventing it. In some cases, even when
eye pressure has been lowered to normal levels, glaucoma
progresses anyway. Thus, neuroprotective agents are desired
to prevent or limit or even recover the damage to the optic
nerve.
Curcumin was reported to possess neuroprotective properties,
which may be effective in the prevention and treatment of
glaucoma. In a chronic high intraocular pressure in vivo
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rat model, pretreatment of curcumin was correlated with
significantly increased cell viability of BV-2 microglia and
the increase presence of ROS and a dramatic decrease in
apoptosis of BV-2 microglia, which indicate that curcumin
may offer neuroprotective effects by inhibiting oxidative
damage to microglia (Yue et al., 2014). Curcumin was
also reported to protect against the loss of retinal ganglion
cells in the same chronic high intraocular pressure model
(Yue et al., 2014). In another research, staurosporine (SS)-
induced ganglion cell death was attenuated by low dosages
of curcumin (<50 M) both in vitro and in vivo (Burugula
et al., 2011). Acute retinal ischemia induced by high intraocular
pressure followed by reperfusion (I/R) is an animal model
for open-angle glaucoma. Dietary curcumin was reported to
have a neuroprotective effect for retinal I/R injury. One
important pathogenic cause for glaucoma is mitochondrial
dysfunction. Mitofusin 2 (mfn2), a mitochondrial fusion protein,
is decreased after retinal I/R injury. Nuclear factor erythroid
2-related factor 2 (Nrf2) has a protective effect against
oxidative stress, and is increased after the retinal I/R injury.
Pretreat of curcumin may reverse the decrease of mfn2 and
the increase of nuclear factor erythroid 2-related factor 2
(Nrf2) in the retinal I/R-induced open-angle glaucoma model
in vivo, indicating that curcumin could maintain the normal
mitochondrial function and alleviate the retinal I/R injury by
regulating the antioxidant system (Wang et al., 2011). Another
important pathogenic cause for glaucoma is excitotoxicity
(Wax and Tezel, 2002). Pretreat of curcumin significantly
attenuates N-methyl-D-aspartate (NMDA)-induced apoptosis in
retinal neuronal/glial cultures in vitro by inhibiting the NR1
subunit of the NMDA receptor (NMDAR) phosphorylation
and NMDAR-mediated Ca2+ increase, demonstrating that
curcumin possesses neuroprotective effects (Matteucci et al.,
2005). Thus, curcumin could be a potential treatment strategy for
glaucoma.
CONCLUSIONS AND OUTLOOK
Since ancient time, curcumin has been used in cooking
and traditional medicine in both China and India. Modern
science has illuminated many molecular basics for which the
pharmaceutical use of curcumin may aid with human ailments.
The selected observational studies on the relationship between
curcumin and anterior segment eye diseases were summarized
in Table 2. The mechanisms underlying the beneficial effects
of curcumin on anterior segment eye diseases are summarized
in Figure 2. In vitro, in vivo, and human clinical studies have
suggested that curcumin has a diverse range of molecular targets,
supporting the concept that it interacts with multiple cellular
signaling pathways and modulates numerous molecular targets.
Curcumin’s harmless nature, low cost, and multiple targeting
potential make it a promising agent for the prevention and
treatment of various eye diseases. Accumulating evidence has
demonstrated its potential therapeutic value. Nevertheless, more
randomized clinical trials are needed in order to solidify our
understanding of its therapeutic potential.
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